Pfizer Advances ELREXFIO Filing Plan as Investors Await Q3 Results

Pfizer reports ELREXFIO Phase 3 success

Pfizer reported that ELREXFIO met the primary endpoint in the Phase 3 MagnetisMM-32 trial for relapsed or refractory multiple myeloma, producing a statistically significant and clinically meaningful progression-free-survival benefit versus standard regimens. The company plans global regulatory submissions, which remain subject to the applicable approval process. The October 29 report said Pfizer shares rose 1.6% to about $29.91, trading as high as $30.18 after the prior close of $29.45.

Investors balance pipeline progress against revenue risks

The ELREXFIO result supported optimism about Pfizer’s oncology pipeline, but investor sentiment remained cautious as the company faces declining COVID-related sales and upcoming patent expirations. A consensus “Hold” rating and a $28.72 price target were cited in the October 29 coverage. The same report said the ability of newer products, including obesity treatments, to generate growth was a central question for investors.

Q3 results are scheduled for November 3

Pfizer was scheduled to report third-quarter 2026 results on November 3 before the market opened, according to October 28 reporting. Consensus estimates cited for the quarter were $16.13 billion in sales and earnings of 72 cents per share. Those figures were forecasts rather than reported results, and full-year 2026 earnings estimates had declined from $2.98 to $2.94 per share over the preceding 30 days.

Product performance may determine the earnings outlook

The October 28 analysis expected higher sales of Vyndaqel, Eliquis, Padcev and Lorbrena to support growth, while newer products Nurtec ODT/Vydura, Cibinqo and Abrysvo were also expected to have risen. Enbrel sales were expected to decline. Lower Comirnaty and Paxlovid revenue was expected to weigh on sales, with consensus estimates of $776.0 million for Pfizer’s direct sales and alliance revenue from Comirnaty and $326.0 million for Paxlovid.

Additional collaboration and dividend developments

Pfizer also agreed to work with Edison Scientific to accelerate research and development, although the financial terms were not disclosed. The collaboration represented a research agreement rather than a disclosed product, procurement order or completed financial transaction. Pfizer declared a quarterly dividend of $0.43 per share, equivalent to a 5.8% annualized yield, while the report put the payout ratio at 226.32%.

The next verifiable milestone

The next scheduled measurement point is Pfizer’s third-quarter earnings report on November 3 before the market opens. Investors will be looking for reported sales and earnings, product-level revenue trends and updated commentary on whether growth outside COVID-related products can offset declining pandemic-related revenue and patent pressures.